STX2 and Thrombocytopenia: delayed and reduced blood urea and creatinine levels and increased survival. Delayed administration of the peptide significantly reduced thrombocytopenia, but had no effect on anemia. This cell-permeable agent shows promise in counteracting Stx2 lethality in a baboon model; outcomes of human trials are awaited.